Thanks, Yusheng.
just so as is ELSA-Seq, behind on X, first program. started early which the let's let's So Slide recap get detection our technology just the
ELSA-Seq machine - model the is So as library early the detection. perform the methylation well methylation a sequencing classification utilizing as targeted assay, to deep at efficient the preparation, the high learning
side, on not, can as low and methylation methylation [indiscernible] tumor tumor call status DNA status, in we also predict the of and to X from of thousands detect inquire low hundreds whether as nanogram the genome the from So ctDNA or the origin. cell-free circulating existing DNA the from the or of blood
has here. listed it technology some highlights being kind So of
correction So just well region building. compatible before single-stranded we library Also for and there And select of with informative reduction signal as deep preparation kind different including model I multiple the most the from apply noise genome sequencing. machine-learning mentioned, conversion. also, as the we the
the talk roadmap. next So about detection slide early development the product
and development last So back this - we the on Biopsy specificity in Advancing demonstrated year, proof-of-concept presented XX.X% which sensitivity under we Meeting. four listed performance X-cancer right Liquid And in Annual XXXX, XX% this At it's is XXXX, year, program achieved Meeting. years Special in this step. X-cancer in the basically And we demonstrated is early type. then And being cancer now, actually And mode. type, first early research - but about it's mean, in the we I we ago, specificity. XXXX AACR started of AACR lung back in been then single-cancer to this
type, model liver as presented mini in this, Congress there. session that And ago, hours Virtual X-cancer oral like a colorectal, now the we ovarian and progress right we which esophageal query in about of cancer just As a X-cancer cancer, actually lung cancer, pancreatic cancer. our Asia ESMO are couple cancer,
to later sensitivity. about in be we'll on achieve XX.X% the talk going this achieve later achieved will we able I'm to under in So, XX.X% cohort, validations we be to able detail specificity, specificity overall slides.
case, results of like are tumor-of-origin XX.X% tumor-of-origin. to predict which about XX% be XX% corrected achieve among we the also We correct, of means, those can able in the the
develop still step For like further. we the currently next
of and terms the and to to we that the head development expanded assay couple neck. type, in type now still further be and and able the follow. under validation X-cancer and right And a add cancer training more, and - addition and cholangio the we'll gastric In including
this product So in roadmap of cancer terms Rock. in is Burning detection program basically the happening development early a
latest stages, included we design next including Shanghai discovery, like, well validation study. detection ESMO cancer Liver on talk we data about [Chao first type result, and this Fudan presented assay marker The early validation. [ph] Asia multiple panel University that from latest call the Chung] Dr. and slide just three as The study Institute as
survey also TCGA So database & a type. profile marker discovery, public key tissue specified change associated methylation GEO we for to and sample in-house the investigate non-cancer cancer with cancer the and X
CpG we divide a capture-based construct result, patient a well this XXX,XXX set. customized we diagnostics clinical select as the sample into assay panel enable from plasma control as site In finally cancer independent validation to As and set early also training detection. cfDNA randomly cancer stage, about to validation a non-cancer
a localization built to training machine-learning of the to derived presence the phase, signal. cancer was identify classifier based During
performance to applied the validate So model evaluate the set was - the independently. subsequently to validation to
to many tested charts the and been patients training the the gender see are and Slide and clinical can in top patient of how of cohort age, comparable - control in overall And and case you overview slide, cancer next validation the individual The including respect cohort. X. we set listed non-cancer training listed bottom and the listed table with have Both in As groups the the characteristic basically validation control. the the status. smoking and
we that stage and we've really diagnosis patient being smoking X, the XX. methylation And like different age cohort, related we of XX% and gender very with to in study this - - As accuracy of stage the status just That's is listed entry. The the careful can are biomarkers. sure That's Slide detection very been this and a it's X type which about call and make cancer time at stage. know, tracked the study is is clinical a or early controlled. age next about of across the sensitivity slide which X, and slide why summary critical means
listed, number on high this highest XX.X% given at gave X graph the sensitivity and grouping the The predicted training validation In we that us tissue the and labeling orange can of number number all sensitivity is for achieve validation red especially and the to the was to recap color. XX. attention included XX%. around next origin the the in The XX.X%. green, In about X. color, of in and bar pay the bit here. bracket sets. indicator are we listed cancer tumor consistent able or the training progression at next performance or talking and separate The XX.X% put sample here. Basically And sensitivity little for stage labeling cancer So X that of slide we are basically And in detection XX.X% cohort, XX% lowest a the stage clinic chart specificity set In showed for validation. overall stages, being with controlled bar a we The from invalidation at lung of is specificity, general, and increased the stage again. sensitivity box this slide And about and doing group. detection rate around the X and training at and cancer red from to we're Slide the different validation cohort categorized sensitivity numbers in by liver the orange stage early X this tumor the XX.X% will be and the call type to this the at the specificities specificity confidence with of basically with the of was along accuracy. training, sensitivity with of a overall. XX.X% in And lot In was which the XX.X%.
be to is which pay the cohort. on - So validation rightmost attention one,
actually achieve So actually actually not basically, better tissue-of-origin. the the to two XX% it's tumor-of-origin, able you cohort from only validation XX% like one the organ achieve means call call, which from is if we'll top be predict to able validation And from be the to correct call XX% be we'll we'll the around organ cohort. the able top
talk to here, going basically about So mentioned next a as just for Yusheng business. slide selection therapy we're the
have two will we topics. So
First, automatic let capture for much the from enrich and you for instrument The method panel on enable library turnkey aka just library current oncology DNA actually Magnis in testing. me - a fully makes sequencing in to update fashion. walkaway BR. method ready give The prep for our solution hybridization some easier
as a panel, test, the XXX-gene many, several liquid - made of our actually we popular which BR year, well this biopsy panel, Magnis is most XXX-gene most the compatible testing. to tissue-based So as now including
able Annual assay, earlier overall which this basically with concordance we the in compatible know, being an is also of XXX-genes and be performance so being this Very you assay selected to panel assay and in Result that Magnis achieved. the useful BR assay Analytical Slide copy presentation So XX cell-free both actually assay fully, Meeting. And platform SNV, look of Target for Magnis this actually it's some kind workflow hospital on of to presented as DNA multiple and fusion by high IO as give validation the kind turn-key which be a And BR will assay. how happened well we XXX-liquid the as you instability highlight better and - to Magnis the we present here a well to our status. and presented equivalent assay of terms OncoScreen lab. exciting on basically just microsatellite this different did like this as is listed number We call assay at the is including scale is small the assay BR variation for both showing the message Annual solution AMP as biomarkers, BR AMP compared OncoCompass week. take-home get as able the very indel, why And is Magnis Meeting Tissue manual biopsy. that This Validation
Chief ask to Shannon me our let Next, licensing on Shannon? the Myriad Operating myChoice give you more Officer, product update activity.
